

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**DTXS Silk Road Investment Holdings Company Limited**  
**大唐西市絲路投資控股有限公司**  
*(Incorporated in Bermuda with limited liability)*  
**(Stock Code: 620)**

**CHANGE OF DIRECTORS  
AND  
CHANGES IN COMPOSITION OF BOARD COMMITTEES**

The Board announces the following change of directors and changes in composition of board committees with effect from 1 February 2021:

1. Dr. Ma Chao has been appointed as an Executive Director, the Chairman of Investment Committee and a member of Remuneration Committee of the Company; and
2. Mr. Xu Lin has resigned as an Executive Director and an Executive Vice-chairman, the Chairman of Investment Committee and a member of Remuneration Committee of the Company.

The board of directors (the “**Board**”) of DTXS Silk Road Investment Holdings Company Limited (the “**Company**”) announces the following change of directors and changes in composition of board committees with effect from 1 February 2021:

**Appointment of Executive Director**

Dr. Ma Chao (“**Dr. Ma**”) has been appointed as an Executive Director of the Company and will serve as the Chairman of Investment Committee and a member of the Remuneration Committee of the Company with effect from 1 February 2021.

Dr. Ma, aged 45, holds a doctoral degree in economics from Northwest University in the People’s Republic of China. Dr. Ma is the president of Da Tang Xi Shi Investment Group Limited\* (大唐西市文化產業投資集團有限公司). Dr. Ma has been in senior management positions at various enterprises for over 20 years and has extensive management experience.

Pursuant to the appointment agreement between Dr. Ma and the Company, the term of his appointment as Executive Director is for an initial term of one year. The appointment agreement can be terminated by either party giving one month’s written notice. Dr. Ma’s appointment of Executive Director is subject to retirement by rotation and re-election in accordance with the bye-laws of the Company and the Listing Rules. Pursuant to the terms of appointment, Dr. Ma is entitled to an aggregate annual remuneration of HK\$300,000. Dr. Ma’s remuneration is recommended by the Remuneration Committee of the Company and determined by the Board with reference to his duties and responsibilities with the Company and prevailing market conditions.

*\* for identification purpose only*

As at the date of this announcement, save as disclosed above, Dr. Ma (i) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (“SFO”); (ii) does not have any relationship with any director, senior management, substantial or controlling shareholder of the Company; (iii) does not hold any other positions with the Company and/or its subsidiaries; and (iv) does not hold any directorship in the last three years immediately preceding the date of this announcement in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed above, there is no other matter relating to the appointment of Dr. Ma that needs to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend its welcome to Dr. Ma on his new appointment.

### **Resignation of Executive Director and Executive Vice-chairman**

Mr. Xu Lin (“**Mr. Xu**”) has resigned as an Executive Director and Executive Vice-chairman of the Company, also ceased to be the Chairman of Investment Committee and a member of the Remuneration Committee of the Company due to his other business commitments with effect from 1 February 2021.

Mr. Xu confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

### **Changes in Composition of Investment Committee and Remuneration Committee**

Following the resignation of Mr. Xu, Dr. Ma was appointed as the Chairman of the Investment Committee and a member of the Remuneration Committee with effect from 1 February 2021. Accordingly, the Investment Committee is composed of Dr. Ma Chao (Chairman), Mr. Yang Xingwen, Mr. Xu Zhihong and Mr. Wong Kwok Tung Gordon Allan; and the Remuneration Committee is composed of Mr. Tse Yung Hoi (Chairman), Dr. Ma Chao and Mr. Kwok Chi Shing.

The Board would like to take this opportunity to express its gratitude to Mr. Xu for his valuable contributions to the Company during his term of office.

By Order of the Board  
**DTXS Silk Road Investment Holdings Company Limited**  
**Lu Jianzhong**  
*Chairman and Executive Director*

Hong Kong, 1 February 2021

*As at the date of this announcement, the Board comprises five Executive Directors, namely Mr. Lu Jianzhong (Chairman), Dr. Ma Chao, Mr. Yang Xingwen, Mr. Xu Zhihong (Chief Executive Officer) and Mr. Wong Kwok Tung Gordon Allan (Deputy Chief Executive Officer); one Non-executive Director, namely, Dr. Cheng Kar-Shun, Henry; and three Independent Non-executive Directors, namely and Mr. Tsang Yok Sing, Jasper, Mr. Tse Yung Hoi and Mr. Kwok Chi Shing.*